TROGLITAZONE

General description

Troglitazone is used to treat type 2 diabetes. It is associated with liver injury. Troglitazone functions as an inducer of cytochrome3A.

Application

Troglitazone has been used as a reagent in adipocyte differentiation medium.

Biochem/physiol Actions

PPARγ agonist; anti-diabetic thiazolidinedione (TZD) with anti-inflammatory and anti-tumor activity; induces apoptosis via a p53 pathway.

Features and Benefits

This compound is featured on the Nuclear Receptors (PPARs) and Potassium Channels pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Pfizer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Preparation Note

Studies using troglitazone have reported that it can increase AMP-activated protein kinase (pAMPK) and phosphorylated acetyl-CoA carboxylase in isolated rat extensor digitorum longus muscles¹. Furthermore, analysis of troglitazone-mediated autophagy is reported to correlate with the stimulation of AMPK α².